Digoxin for Worsening Chronic Heart Failure. Underutilized and Underrated*.

JACC: Heart Failure

Volumn 4, Issue 5, 2016, Pages 365-367

  Ambrosy, Andrew P ^a   Pang, Peter S ^b   Gheorghiade, Mihai ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Digoxin; Heart failure; Mortality; Outcomes; Readmissions

Indexed keywords

DIGOXIN; PLACEBO; CARDIOTONIC AGENT;

DIGOXIN BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EDITORIAL; FUNCTIONAL STATUS; HEART FAILURE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; UNSPECIFIED SIDE EFFECT; CHRONIC DISEASE;

CARDIOTONIC AGENTS; CHRONIC DISEASE; DIGOXIN; HEART FAILURE; HUMANS;

EID: 84964702379     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2016.03.005     Document Type: Editorial

References (23)

1. Ambrosy A.P., Butler J., Ahmed A., et al. The use of digoxin in patients with worsening chronic heart failure: reconsidering an old drug to reduce hospital admissions. J Am Coll Cardiol 2014, 63:1823-1832.
2. Khan S.S., Gheorghiade M. Digoxin use in atrial fibrillation: a critical reappraisal. Lancet 2015, 385:2330-2332.
3. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2013, 62:e147-239.
4. Patel N., Ju C., Macon C., et al. Temporal trends of digoxin use in patients hospitalized with heart failure: analysis from the American Heart Association Get With The Guidelines-Heart Failure Registry. J Am Coll Cardiol HF 2016, 4:348-356.
5. Hauptman P.J., Blume S.W., Lewis E.F., Ward S. Digoxin toxicity and use of digoxin immune fab: insights from a national hospital database. J Am Coll Cardiol HF 2016, 4:357-364.
6. Yusuf S., Wittes J., Bailey K., Furberg C. Digitalis-a new controversy regarding an old drug. The pitfalls of inappropriate methods. Circulation 1986, 73:14-18.
7. Uretsky B.F., Young J.B., Shahidi F.E., Yellen L.G., Harrison M.C., Jolly M.K. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol 1993, 22:955-962. PROVED Investigative Group.
8. Packer M., Gheorghiade M., Young J.B., et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 1993, 329:1-7.
9. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997, 336:525-533. Digitalis Investigation Group.
10. Gheorghiade M., Hall V., Lakier J.B., Goldstein S. Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure. J Am Coll Cardiol 1989, 13:134-142.
11. Gheorghiade M., St Clair J., St Clair C., Beller G.A. Hemodynamic effects of intravenous digoxin in patients with severe heart failure initially treated with diuretics and vasodilators. J Am Coll Cardiol 1987, 9:849-857.
12. Ahmed A., Rich M.W., Fleg J.L., et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 2006, 114:397-403.
13. Williamson K.M., Thrasher K.A., Fulton K.B., et al. Digoxin toxicity: an evaluation in current clinical practice. Arch Inter Med 1998, 158:2444-2449.
14. Mahdyoon H., Battilana G., Rosman H., Goldstein S., Gheorghiade M. The evolving pattern of digoxin intoxication: observations at a large urban hospital from 1980 to 1988. Am Heart J 1990, 120:1189-1194.
15. Gheorghiade M., Patel K., Filippatos G., et al. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail 2013, 15:551-559.
16. Ahmed A., Rich M.W., Love T.E., et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006, 27:178-186.
17. Rathore S.S., Wang Y., Krumholz H.M. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002, 347:1403-1411.
18. Adams K.F., Patterson J.H., Gattis W.A., et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol 2005, 46:497-504.
19. Gheorghiade M., Fonarow G.C., van Veldhuisen D.J., et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J 2013, 34:1489-1497.
20. Whitbeck M.G., Charnigo R.J., Khairy P., et al. Increased mortality among patients taking digoxin-analysis from the AFFIRM study. Eur Heart J 2013, 34:1481-1488.
21. Butler J., Braunwald E., Gheorghiade M. Recognizing worsening chronic heart failure as an entity and an end point in clinical trials. JAMA 2014, 312:789-790.
22. Butler J., Fonarow G.C., Gheorghiade M. Strategies and opportunities for drug development in heart failure. JAMA 2013, 309:1593-1594.
23. Gheorghiade M., Braunwald E. Reconsidering the role for digoxin in the management of acute heart failure syndromes. JAMA 2009, 302:2146-2147.